The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study
Not yet recruitingOBSERVATIONAL
Enrollment
400
Participants
Timeline
Start Date
August 1, 2025
Primary Completion Date
March 31, 2027
Study Completion Date
December 31, 2027
Conditions
Hepatocellular Carcinoma (HCC)Real World Study
All Listed Sponsors
lead
Tianjin Medical University Cancer Institute and Hospital
OTHER
NCT07078292 - The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study | Biotech Hunter | Biotech Hunter